| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V36932-1mg |
≥99% | ￥2310.00 |
货期：3-5天 | - | - | - | - |
|
V36932-5mg |
≥99% | ￥4870.00 |
货期：3-5天 | - | - | - | - |
|
V36932-10mg |
≥99% | ￥6950.00 |
货期：3-5天 | - | - | - | - |
|
V36932-25mg |
≥99% | ￥9870.00 |
货期：3-5天 | - | - | - | - |
|
V36932-50mg |
≥99% | ￥13900.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | NEP. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | While the NEP inhibitors have no significant effect on body weight, food and water intake, mean blood pressure or creatinine levels, they do increase cGMP levels in the urine and affected hematopoiesis in an anti-inflammatory way. Moreover, a-SMA deposition in the kidney cortex is inversely correlated with cGMP elevation suggesting a NEP dependent antifibroti effect. High quality mRNA profiles are obtained with at least 8 independent samples per treatment group. The data confirms the cGMP dependent anti-fibrotic action of Sol-1 and further supports the potential therapeutic actions of this neutral endopeptidase inhibitor. | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京